Marshall Wace’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.2M | Sell |
598,378
-15,222
| -2% | -$512K | 0.02% | 774 |
|
|
2025
Q4 | $26.3M | Buy |
613,600
+12,267
| +2% | +$462K | 0.02% | 541 |
|
|
2025
Q3 | $17M | Buy |
601,333
+232,383
| +63% | +$6.95M | 0.02% | 723 |
|
|
2025
Q2 | $6.91M | Buy |
368,950
+157,202
| +74% | +$2.98M | 0.01% | 992 |
|
|
2025
Q1 | $3.81M | Buy |
+211,748
| New | +$4.3M | ﹤0.01% | 1189 |
|
|
2024
Q2 | – | Sell |
-43,856
| Closed | -$649K | – | 2888 |
|
|
2024
Q1 | $649K | Buy |
+43,856
| New | +$591K | ﹤0.01% | 1832 |
|
|
2023
Q4 | – | Sell |
-3,602
| Closed | -$38.9K | – | 2543 |
|
|
2023
Q3 | $38.9K | Buy |
+3,602
| New | +$43.3K | ﹤0.01% | 2098 |
|
|
2023
Q2 | – | Sell |
-17,273
| Closed | -$228K | – | 2906 |
|
|
2023
Q1 | $228K | Buy |
+17,273
| New | +$274K | ﹤0.01% | 2378 |
|
|
2021
Q4 | – | Sell |
-6,922
| Closed | -$251K | – | 4225 |
|
|
2021
Q3 | $251K | Buy |
+6,922
| New | +$272K | ﹤0.01% | 2715 |
|
|
2020
Q3 | – | Sell |
-2,730
| Closed | -$50K | – | 1875 |
|
|
2020
Q2 | $50K | Buy |
+2,730
| New | +$49.1K | ﹤0.01% | 1478 |
|
|
2019
Q4 | – | Sell |
-70,903
| Closed | -$1.33M | – | 2006 |
|
|
2019
Q3 | $1.33M | Sell |
70,903
-53,753
| -43% | -$1.11M | 0.01% | 872 |
|
|
2019
Q2 | $3.25M | Buy |
124,656
+10,016
| +9% | +$226K | 0.03% | 623 |
|
|
2019
Q1 | $2.95M | Buy |
114,640
+81,023
| +241% | +$1.85M | 0.03% | 636 |
|
|
2018
Q4 | $773K | Buy |
33,617
+20,277
| +152% | +$572K | 0.01% | 984 |
|
|
2018
Q3 | $428K | Buy |
13,340
+10,949
| +458% | +$329K | ﹤0.01% | 955 |
|
|
2018
Q2 | $68K | Buy |
+2,391
| New | +$85.1K | ﹤0.01% | 678 |
|
|
2017
Q1 | – | Sell |
-13,705
| Closed | -$326K | – | 671 |
|
|
2016
Q4 | $326K | Sell |
13,705
-7,146
| -34% | -$205K | ﹤0.01% | 877 |
|
|
2016
Q3 | $765K | Buy |
+20,851
| New | +$598K | 0.01% | 755 |
|
|
2016
Q2 | – | Sell |
-84,793
| Closed | -$1.76M | – | 1136 |
|
|
2016
Q1 | $1.76M | Buy |
84,793
+12,180
| +17% | +$300K | 0.02% | 589 |
|
|
2015
Q4 | $2.2M | Hold |
72,613
| – | – | 0.02% | 547 |
|
|
2015
Q3 | $1.79M | Buy |
72,613
+2,874
| +4% | +$85.8K | 0.02% | 480 |
|
|
2015
Q2 | $2.24M | Buy |
69,739
+12,444
| +22% | +$475K | 0.03% | 456 |
|
|
2015
Q1 | $2.04M | Buy |
57,295
+20,943
| +58% | +$574K | 0.03% | 464 |
|
|
2014
Q4 | $825K | Buy |
+36,352
| New | +$735K | 0.01% | 594 |
|
|
2014
Q3 | – | Sell |
-17,976
| Closed | -$653K | – | 1015 |
|
|
2014
Q2 | $653K | Buy |
+17,976
| New | +$611K | 0.01% | 567 |
|
Other funds holding RIGL
AC
VCM
Marshall Wace's RIGL Position: Q1 2026 in Review
Marshall Wace reduced its Rigel Pharmaceuticals (RIGL) stake by 2.5% in Q1 2026, selling an estimated $512K and leaving 598,378 shares worth $16.2M. The position accounts for 0.02% of the portfolio, ranked #774.
Marshall Wace first reported a position in RIGL in Q2 2014 and has held it in 25 quarters since. The position peaked at $26.3M in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Marshall Wace held 598,378 shares of Rigel Pharmaceuticals worth $16.2M as of Q1 2026.
- Marshall Wace sold 15,222 Rigel Pharmaceuticals shares in Q1 2026, an estimated $512K.
- Rigel Pharmaceuticals made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #774 holding.
- Marshall Wace first reported a position in Rigel Pharmaceuticals in Q2 2014 and has held it in 25 quarters since.
- Marshall Wace's Rigel Pharmaceuticals position peaked at $26.3M in Q4 2025.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.